Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Aster DM Healthcare reports robust Q2 growth, PAT up 46%

EditorHari G
Published 11/15/2023, 04:52 AM
Updated 11/15/2023, 04:52 AM
© Reuters.

DUBAI - Aster DM Healthcare, a leading healthcare provider in the Middle East and India, has announced a strong financial performance for the second quarter of the fiscal year 2024. The company saw its operational revenue climb to Rs. 3,317 Crores, marking an 18% year-over-year (YoY) growth. This increase is partly attributed to the successful ramp-up of new hospitals and the overall consolidated revenue growth.

The company's consolidated EBITDA for Q2 FY24 also showed a significant rise of 21%, reaching Rs. 393 Crores. Profit after tax (PAT) experienced a substantial increase, surging by 46% to Rs. 67 Crores. This figure includes considerations for new hospitals and exceptional items, showcasing the company's ability to effectively integrate and capitalize on its expansions.

Dr. Azad Moopen, Chairman of Aster DM Healthcare, credited these positive results to the strategic initiatives implemented across the company's network.

Looking at the first half of FY24, Aster DM Healthcare's financials are equally impressive. The operational revenue increased by 19% YoY to Rs. 6,532 Crores. EBITDA followed suit with a robust 28% growth, amounting to Rs. 791 Crores. PAT stood out with a remarkable 77% YoY increase to Rs. 162 Crores after adjusting for exclusions.

Alisha Moopen, Deputy Managing Director at Aster DM Healthcare, highlighted the success of their GCC operations which reported a 16% YoY revenue growth (Rs. 2,383 Crs). The GCC business's EBITDA rose by 23% (Rs. 236 Crores), and EBITDA margins improved to 10%. These achievements were linked to strategic investments made in the previous fiscal year that are now yielding results.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Further showcasing its financial health, Aster DM Health reported that its net sales in September surged by an impressive 34.73% compared to September of the previous year, reaching Rs 509.21 crore. The quarterly net profit also grew by 3.69%, totaling Rs. 59.06 crore. EBITDA saw a healthy growth of 12.97%, standing at Rs. 106.54 crore, while earnings per share (EPS) increased from Rs.1.15 in September 2022 to Rs.1.19.

Investors have responded positively to Aster DM Healthcare's performance with the company's shares closing at ₹340.25 on BSE as of Monday, reflecting a six-month return of 33.35% and an annual return of 45.28%.

These results reflect Aster DM Healthcare's continued focus on expanding its services and improving operational efficiencies across its network of healthcare facilities, which has translated into strong financial growth and increased shareholder value.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.